Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657514 | 0.83 | ALDH1A1 (0.58) | ALDH1A1POLBKMT2ATLR8CA12 | |
| SCHEMBL15332214 | 0.81 | KMT2A (0.38) | ALDH1A1POLBKMT2ATLR8CA12 | |
| SCHEMBL16654829 | 0.81 | ACHE (0.39) | ALDH1A1POLBKMT2ATLR8ARG1 | |
| SCHEMBL20626690 | 0.81 | ACHE (0.39) | ALDH1A1POLBKMT2ATLR8ARG1 | |
| SCHEMBL16654830 | 0.81 | ACHE (0.39) | ALDH1A1POLBKMT2ATLR8ARG1 | |
| SCHEMBL2086433 | 0.80 | ADORA2B (0.35) | — | |
| SCHEMBL15330327 | 0.79 | TLR8 (0.39) | ALDH1A1POLBKMT2ATLR8CA12 | |
| SCHEMBL16664096 | 0.79 | ALDH1A1 (0.37) | ALDH1A1POLBKMT2ATLR8CA12 | |
| SCHEMBL15333000 | 0.79 | CCNE1 (0.37) | ALDH1A1POLBKMT2ATLR8CA12 | |
| SCHEMBL5655364 | 0.78 | TLR8 (0.57) | ALDH1A1POLBKMT2ATLR8CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172831-B2 | Catalytic scavengers of organophosphates to potentiate butyrylcholinesterase (hBChE) as a catalytic bioscavenger and methods for making and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-08 | — | — | US | disclosed |
| US-20160256438-A1 | CATALYTIC SCAVENGERS OF ORGANOPHOSPHATES TO POTENTIATE BUTYRYLCHOLINESTERASE (hBChE) AS A CATALYTIC BIOSCAVENGER AND METHODS FOR MAKING AND USING THEM | UNIV CALIFORNIA (US) | 2016-09-08 | — | — | US | disclosed |
| EP-3057582-A1 | CATALYTIC SCAVENGERS OF ORGANOPHOSPHATES TO POTENTIATE BUTYRYLCHOLINESTERASE (BCHE) AS A CATALYTIC BIOSCAVENGER AND METHODS FOR MAKING AND USING THEM | The Regents of the University of California (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015057822-A1 | CATALYTIC SCAVENGERS OF ORGANOPHOSPHATES TO POTENTIATE BUTYRYLCHOLINESTERASE (BCHE) AS A CATALYTIC BIOSCAVENGER AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172831-B2 | Catalytic scavengers of organophosphates to potentiate butyrylcholinesterase (hBChE) as a catalytic bioscavenger and methods for making and using them | BCHE, ACHE, HMBS | ALDH1A1 448/4885POLB 1428/4885KMT2A 2289/4885 |
| US-20160256438-A1 | CATALYTIC SCAVENGERS OF ORGANOPHOSPHATES TO POTENTIATE BUTYRYLCHOLINESTERASE (hBChE) AS A CATALYTIC BIOSCAVENGER AND METHODS FOR MAKING AND USING THEM | BCHE, ACHE, HMBS | ALDH1A1 448/4885POLB 1428/4885KMT2A 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.